

## **CERENIS THERAPEUTICS HOLDING**

Limited company with share capital of € 915,413.15  
Registered Office: 33-43 avenue Georges Pompidou – Bât. D  
481 637 718 RCS TOULOUSE

### **INFORMATION RELATED TO THE CANDIDACY OF JEAN-LOUIS DASSEUX TO SERVE AS DIRECTOR PRESENTED TO THE COMBINED GENERAL MEETING OF JUNE 25, 2018**

**SURNAME AND NAME:** Jean-Louis DASSEUX

**AGE:** 59

#### **PROFESSIONAL REFERENCES AND ACTIVITIES IN OTHER COMPANIES OVER THE PAST FIVE YEARS:**

Dr. Jean-Louis Dasseux is the founder of Cerenis and one of the world's leading experts in lipid metabolism, lipid-protein interaction, and cardiovascular disease. He has more than 25 years of experience in the pharmaceutical industry. Dr. Dasseux has generated more than 85 patents related to HDL, RLT, the treatment of cardiovascular disease and the targeted delivery of active ingredients, particularly in oncology. He was the inventor of a high-capacity reverse lipid transport peptide HDL mimetic drug (ETC-642) and a series of small molecule compounds that raise blood HDL levels (ETC-1001 and ETC-1002). He held management positions at Esperion Therapeutics (Sr. Vice President of Business Development & Technologies, and Vice President of Chemistry & Technologies), a company that developed the first generation of HDL mimetic drugs (pro-apoA-I, apoA-I Milano, peptide apoA-I) until the company was bought by Pfizer for USD 1.3 billion. Before joining Esperion, he was Research Director at Fournier, the French pharmaceutical group, where he set up and headed the research center in Heidelberg, Germany. Jean-Louis Dasseux holds an MBA from the Ross School of Business of the University of Michigan, in the United States. He earned his Master's Degree in Biochemistry from Bordeaux II University and his Ph.D. in Physical Chemistry from Bordeaux I University. He has held postdoctoral research positions at the Department of Chemistry of the University of Laval in Quebec, the Department of Physics at the University of Tennessee in Knoxville, Tennessee, and at the European Molecular Biology Laboratory in Heidelberg, Germany.

#### **POSITION HELD IN THE COMPANY:**

Director and Chief Executive Officer

#### **NUMBER OF THE COMPANY'S SHARES HELD:**

1,230,602